Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DVY0C6
|
|||
| Drug Name |
LY3372689
|
|||
| Synonyms |
LY3372689; U0SGP6ZX2V; LY-3372689; UNII-U0SGP6ZX2V; 2241514-56-5; Acetamide, N-(4-fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)-1-piperidinyl)methyl)-2-thiazolyl)-; CHEMBL5095251; SCHEMBL20421995; GTPL11953; GLXC-25705; EX-A6549; MS-26295; HY-144681; CS-0433932; N-(4-Fluoro-5-(((2S,4S)-2-methyl-4-((5-methyl-1,2,4-oxadiazol-3-yl)methoxy)piperidin-1-yl)methyl)thiazol-2-yl)acetamide; N-[4-fluoro-5-[[(2S,4S)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]piperidin-1-yl]methyl]-1,3-thiazol-2-yl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H22FN5O3S
|
|||
| Canonical SMILES |
CC1CC(CCN1CC2=C(N=C(S2)NC(=O)C)F)OCC3=NOC(=N3)C
|
|||
| InChI |
InChI=1S/C16H22FN5O3S/c1-9-6-12(24-8-14-19-11(3)25-21-14)4-5-22(9)7-13-15(17)20-16(26-13)18-10(2)23/h9,12H,4-8H2,1-3H3,(H,18,20,23)/t9-,12-/m0/s1
|
|||
| InChIKey |
FRVXHWNHGWUTQO-CABZTGNLSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Beta-N-acetylhexosaminidase (OGA) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05063539) Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.